N/A N=131

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Advanced Hepatocellular Carcinoma

Bottom Line

View on ClinicalTrials.gov: NCT04862949 ↗

Enrolled (actual)

131

Serious AEs

12.2%

Results posted

Dec 2025

Primary outcome: Primary: Percentage of Lesions With Organ-specific Response — 29.8; 28.3; 40.5; 29.1 Percentage of Units (lesions)

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: Atezolizumab plus bevacizumab (Drug)
Age: Adult, Older Adult · 19+ yrs
Sex: All
Sponsor: CHA University
Primary completion: Dec 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage of Lesions With Organ-specific Response	29.8; 28.3; 40.5; 29.1; 19.0	—

Summary

Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related deaths globally and in Korea. Many patients diagnosed at advanced stage, and systemic therapy is mainstay of treatment in patients with advanced HCC. However, immune-checkpoint inhibitor (ICI) monotherapy did not significantly improve overall survival in phase III studies. According to previous retrospective analyses, ICI treatment in advanced HCC showed different organ-specific responses. The intrahepatic HCC was the least responsive organ to ICI treatment. The failure of phase III trials of ICI monotherapy may have been attributed to different organ-specific response pattern of ICIs. Combination of atezolizumab plus bevacizumab is expected to overcome the immunosuppressive microenvironment of liver and may enhance intrahepatic response of ICI.

Eligibility Criteria

Inclusion Criteria

Confirmed HCC pathological or non-invasive assessment according to American Association for the Study of Liver Diseases (AASLD) criteria
ECOG performance status 0 or 1
Patients who received Atezolizumab and Bevacizumab combination therapy as first-line systemic treatment for unresectable HCC
Barcelona Clinic Liver Cancer (BCLC) stage B or C
Child-Pugh class A
Measurable lesion
Adequate hematologic and organ function

Exclusion Criteria

History of autoimmune disease
Concomitant anticoagulation at therapeutic doses. Low dose aspirin for
cardio protection is permitted.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04862949). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.